Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
UNIVERSIDADE DE SANTIAGO DE COMPOSTELA has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units. GULLEDGE, BRIAN M is the busiest examiner, with 1 pending matter.
The portfolio’s pending activity is spread across three examination settings. This may lead to different treatment of biological or pharmaceutical claim limitations, making separate review of claim construction, disclosure support, and cited references important for each application.
No examiner is shown as handling more than the stated 1 pending matter. Counsel can coordinate scientific terminology and evidence at the portfolio level, while keeping amendments and patentability arguments tied to the particular record before each examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Multi-statute (no §101) | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GULLEDGE, BRIAN M | 1 | 55.9% | +26.2% |
| SINGH, SATYENDRA K | 1 | 61.5% | +67.9% |
| CULLEN, SEAN P | 1 | 69.2% | +28.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245123 | SUPRAMOLECULAR FLUID | CULLEN, SEAN P | 11d overdue |
| 18720623 | METHOD FOR PRODUCING POLYHYDROXYALKANOATES (PHAS) AND TRIACYLGLYCERIDES (TAGS) | SINGH, SATYENDRA K | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245123 | SUPRAMOLECULAR FLUID | CULLEN, SEAN P | 11d overdue |
| 18836472 | MICROSPHERES FOR EXTENDED RELEASE OF FENOFIBRATE | GULLEDGE, BRIAN M | — |
| 18720623 | METHOD FOR PRODUCING POLYHYDROXYALKANOATES (PHAS) AND TRIACYLGLYCERIDES (TAGS) | SINGH, SATYENDRA K | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1657 | 1 |
| 1725 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18836472 | MICROSPHERES FOR EXTENDED RELEASE OF FENOFIBRATE | GULLEDGE, BRIAN M | 1699 | §103 | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18720623 | METHOD FOR PRODUCING POLYHYDROXYALKANOATES (PHAS) AND TRIACYLGLYCERIDES (TAGS) | SINGH, SATYENDRA K | 1657 | §103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
| 18245123 | SUPRAMOLECULAR FLUID | CULLEN, SEAN P | 1725 | §102§103§112 | Non-Final OA | 11d overdue | Pending | Mar 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSIDADE DE SANTIAGO DE COMPOSTELA has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Brian M Gulledge has the most, with 1 of UNIVERSIDADE DE SANTIAGO DE COMPOSTELA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
